drugset
drugset / Trial / NCT01447485

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

NCT01447485 ↗

Phase 1 Completed 12 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

This study will assess the pharmacokinetics and safety following single dose of valsartan in Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome.

Timeline

Start
2011-08
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Small molecule 20 mg —
Subject Valsartan Small molecule 40 mg —

Indications

chronic kidney disease essential hypertension nephrotic syndrome